Nu-Med Plus (NUMD) Net Income towards Common Stockholders Growth (5y) (2017 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Nu-Med Plus | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 52.24% |
| Sep 30, 2025 | 51.67% |
| Jun 30, 2025 | 58.15% |
| Mar 31, 2025 | 33.51% |
| Dec 31, 2024 | 45.01% |
| Sep 30, 2024 | 34.13% |
| Jun 30, 2024 | 41.31% |
| Mar 31, 2024 | 44.86% |
| Dec 31, 2023 | 30.56% |
| Sep 30, 2023 | 49.85% |
| Jun 30, 2023 | 31.72% |
| Mar 31, 2023 | 27.16% |
| Dec 31, 2022 | -59.48% |
| Sep 30, 2022 | 15.22% |
| Jun 30, 2022 | 11.43% |
| Mar 31, 2022 | 1.95% |
| Dec 31, 2021 | -16.21% |
| Sep 30, 2021 | 29.72% |
| Jun 30, 2021 | -7.07% |
| Mar 31, 2021 | -42.77% |
| Dec 31, 2020 | -21.27% |
| Sep 30, 2020 | -8.68% |
| Jun 30, 2020 | -18.71% |
| Mar 31, 2020 | -5.97% |
| Dec 31, 2019 | 16.78% |
| Sep 30, 2019 | 8.51% |
| Jun 30, 2019 | -5.01% |
| Mar 31, 2019 | -24.29% |
| Sep 30, 2018 | -72.99% |
| Jun 30, 2018 | -39.39% |
| Mar 31, 2018 | -11.91% |
| Dec 31, 2017 | 75.49% |
| Mar 31, 2017 | -27.50% |